Suppression of prostate cancer using a targeted clostridial neurotoxin
AssigneeIpsen Bioinnovation Limited
InventorsFrederic Madec, Philip Lecane, Philip Marks, Keith Foster
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
Claims14
A method of treating cancer, the method comprising administering to a patient in need thereof an effective amount of a polypeptide comprising an amino acid sequence comprising:
- a) a non-cytotoxic protease comprising a clostridial neurotoxin endopeptidase capable of cleaving a protein of the exocytic fusion apparatus in a pituitary cell;
- b) a targeting moiety that is capable of binding to a growth hormone-releasing hormone (GHRH) receptor on the pituitary cell;
- and
- c) a translocation domain comprising a clostridial neurotoxin translocation domain capable of translocating the protease from within the endosome of the pituitary cell, across the endosomal membrane, and into the cytosol;
- wherein:
- the pituitary cell is a normal, non-diseased, noncancerous cell;
- the method reduces secretion of growth hormone from the cell;
- the cancer is prostate cancer;
- and
- the amino acid sequence is effective at treating prostate cancer.
Dependencies are inferred from the claim text.